Comment from Chad Zenk-Tills
AnonymousSupportIndividual
Summary: An individual is expressing support for the FDA's efforts to expand regulatory pathways for New Approach Methodologies (NAMs) in drug development. They argue that technologies like organ-on-chip and computational models provide more human-relevant data than traditional animal testing and should be proactively accepted by the FDA.
I am writing to express my support for the FDA’s continued efforts to expand regulatory pathways for scientifically validated alternatives to animal testing in drug development. Methods such as human cell-based testing, organ-on-chip technology, and computational models offer meaningful potential to improve how well preclinical data translates to human outcomes — an area where traditional animal studies have well-documented limitations. I encourage the FDA to take a proactive approach in evaluating and accepting New Approach Methodologies (NAMs) where they meet appropriate scientific standards. Modernizing these pathways is important both for the integrity of the science and for reducing unnecessary reliance on animal studies when more human-relevant options exist.